Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…
Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Life science researchers and drug discovery scientists today work in what, in my view, will be remembered in the future as the beginning of a “golden era” where the power of genetic information is connected to a wide range of other healthcare and lifestyle data to support better understanding of
Oh the Places You’ll Go (with 1 billion regressions an hour) explores the partnership with Alnylam to access and understand the data from the UK Biobank project. Click the image below to view the full video: